Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
281-300 of 653 trials

Benzodiazepine Dependence: Stabilizing Treatment Study

We are examining how a stable dose of benzodiazepines affects people with benzodiazepine dependence who are also receiving opioid therapy. The study looks at impacts on drug use, mental and physical health, and overall quality of life.

Benzodiazepine Dependence1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePsychiatry

Idiopathic Pulmonary Fibrosis: CMR316 Safety Study

We are assessing the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis. This study aims to understand how well the treatment is tolerated.

Idiopathic Pulmonary Fibrosis1-2 yearsSafety phase (I)Internal MedicinePulmonology

Uncontrolled Asthma: Dupilumab vs. High Dose ICS

We are studying whether adding dupilumab to medium dose asthma medication helps reduce severe asthma attacks better than increasing the dose of current treatments. This trial is for adolescents and adults with uncontrolled asthma.

Asthma1-2 yearsMonitoring phase (IV)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyPulmonology

Meningococcal Disease: New Pentavalent Vaccine for Children

We are studying a new vaccine to see if it is safe and effective for healthy children, toddlers, and infants against meningococcal disease. The trial compares this vaccine with currently licensed options to evaluate immune responses.

Meningococcal Immunization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Crohn's Disease: AZD7798 Treatment Study

We are investigating how well AZD7798 works and its safety for people with moderate to severe Crohn's disease. This study will help us understand its effects on disease activity and overall health.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

ANCA-Associated Vasculitis: LNP023 (iptacopan) Study

We are testing a new treatment for patients with active ANCA-associated vasculitis to see if it helps achieve lasting remission compared to standard care. The study will also evaluate its impact on disease relapse and kidney health.

Microscopic PolyangiitisGranulomatosis with Polyangiitis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Intranasal COVID-19 Vaccine: LVT-001

We are studying a new intranasal booster vaccine for COVID-19 to see if it is safe and more effective than the standard mRNA vaccine. This trial is for healthy adults who want to help improve COVID-19 vaccination strategies.

COVID-191-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

Advanced Solid Tumors: BT5528 Treatment Study

We are testing a new drug, BT5528, for patients with advanced solid tumors that express EphA2. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Breast Cancer: Fezolinetant for Hot Flashes

We are studying whether fezolinetant can help reduce hot flashes in women with hormone receptor-positive breast cancer receiving hormone therapy. The trial also looks at how this treatment affects quality of life and sleep.

Hot Flashes1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteEndocrinologyOncology

Dementia with Lewy Bodies: Ambroxol Study

We are investigating whether Ambroxol can improve cognitive and functional abilities in people with early Dementia with Lewy Bodies. The study also looks at its effects on sleep disturbances and other related symptoms.

Dementia with Lewy Bodies1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessStandard MedicinesNeurologyPsychiatry

Hidradenitis Suppurativa: Lutikizumab Study

We are evaluating the effectiveness and safety of lutikizumab for treating moderate to severe hidradenitis suppurativa in adults and adolescents. This study compares lutikizumab to a placebo to see how well it works.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

Safety Study of IMP761 Immunosuppressive Antibody

We are testing the safety of a new immunosuppressive antibody in healthy volunteers. This study aims to understand how the antibody affects the body before further testing in patients.

Autoimmunity1-2 yearsSafety phase (I)Infectious Diseases

Colorectal Cancer: SGM-101 Imaging Study

We are testing a new imaging agent to help surgeons detect brain metastases from colorectal cancer during surgery. This study aims to see how well it works and its safety for patients.

Brain Metastases1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncology

Rectal Polyps: SGM-101 Fluorescent Tracer Study

We are investigating a new imaging technique using SGM-101 to help identify cancerous and non-cancerous tissues in patients with rectal polyps. This study aims to improve how doctors detect early-stage rectal cancer.

Early Rectal Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Knee Surgery Pain Relief: Oral vs. IV Medications

We are comparing the effectiveness of oral pain relief to intravenous options for patients after knee arthroscopy. This study aims to see which method better manages pain and affects recovery.

Postoperative Pain Relief1-2 yearsMonitoring phase (IV)Standard MedicinesOrthopedics and TraumatologyOtolaryngology

Ulcerative Colitis: CICR-NAM Treatment Study

We are testing a new oral medication for people with mild to moderately active ulcerative colitis. The goal is to see if it helps improve symptoms and overall gut health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterology

Tezepelumab for Progressive Pulmonary Fibrosis

We are studying whether Tezepelumab can help reduce symptoms and improve lung function in people with progressive pulmonary fibrosis and high eosinophil levels. This trial compares the medication to a placebo to evaluate its effectiveness.

Interstitial Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePulmonology

Advanced Melanoma: Relatlimab with Nivolumab Study

We are investigating whether combining Relatlimab with Nivolumab helps people with untreated advanced melanoma live longer and have better outcomes than Nivolumab alone.

Metastatic Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

The LIFE-MET Study: Metformin and Lifestyle Changes in Early Puberty

We are investigating how Metformin and lifestyle interventions may influence growth and development in girls with overweight and early puberty. The study looks at changes in body composition and pubertal progression.

Precocious Puberty and Overweight1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Sedation Methods in TAVR Procedures

We are comparing different sedation techniques for patients undergoing Transcatheter Aortic Valve Replacement. The goal is to see if one method reduces breathing problems and confusion after the procedure.

Aortic Stenosis1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyGastroenterologyInternal MedicineOtolaryngologyPsychiatry